Expand your knowledge.

Alternative Therapies for NASH

September 28, 2022, 10AM PT/1PM EST

Listen to Key Opinion Leader Dr. Naim Alkhouri discuss the latest data regarding alternative therapies for NASH patients with metabolic disorders. Topics include:

  • the latest data and guidelines with respect to anti-obesity medications for the treatment of NASH
  • the value of digital tools in NASH resolution
  • which patients respond best to bariatric surgery and what the long-term impact is on NASH

Featured Speaker(s):

Dr. Naim Alkhouri, Sonicincytes webinar

Dr. Naim Alkhouri

Naim Alkhouri, MD
Chief Medical Officer,
Chief of Transplant Hepatology,
Director of the Fatty Liver Program
Arizona Liver Health

Naim Alkhouri, M.D., is the Chief Medical Officer (CMO), Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ. Prior to joining ALH, Dr. Alkhouri served as the director of the Metabolic Health Center at the Texas Liver Institute and Associate Professor of Medicine and Pediatrics at the University of Texas (UT) Health in San Antonio, TX.

Dr. Alkhouri completed his Gastroenterology and Transplant Hepatology training at the renowned Cleveland Clinic, where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic at the Cleveland Clinic Digestive Disease and Surgery Institute.

An author of over 200 publications, Dr. Alkhouri is considered a key opinion leader in the field of NASH therapeutics and serves as a member of the AASLD NASH Special Interest Group (NASH SIG). He acts as an advisor to many pharmaceutical and biomarker development companies and is Principal Investigator on several multicenter global NASH trials.

Dr. Alkhouri is the recipient of a number of research awards, including the American College of Gastroenterology Junior Faculty Development Award.

Share With Your Network